Cannabis, Anxiety and PTSD: Risks, Standard Treatment, the Thai Prescription Rules and Practical Steps (Part 2 of 2)

High-THC cannabis can reliably cause anxiety, paranoia and panic in people who are prone to them. In people with a personal or family history of psychosis, it is linked to earlier and more severe symptoms. CBD can raise the blood levels of some common anxiety medicines. In Thailand, cannabis flower is a controlled herb, and you can get it only with a PT 33 prescription. This part explains the risks, how cannabis fits with standard anxiety treatment, the Thai rules, and the steps patients and doctors can take.

Part 1 reached three main findings. THC lowers anxiety at low doses and raises it at high doses, and the turning point differs from person to person. CBD (cannabidiol, a compound that does not cause intoxication) helped in short studies of social anxiety. It did not help in an exposure-therapy trial. In post-traumatic stress disorder (PTSD), the main trial of smoked cannabis found it no better than placebo, a dummy product.

This is Part 2. Part 1: Cannabis, Anxiety and PTSD: THC Dose, the CBD Trials and What the Evidence Shows (Part 1 of 2)

Risks and side effects

Worse anxiety and panic attacks

At a high enough dose, high-THC cannabis reliably causes anxiety and paranoia in people who are prone to them. Paranoia is the feeling of being watched or threatened without reason. This is a predictable effect, not a rare side effect.

Hospital emergency departments regularly see panic attacks triggered by cannabis. Many involve high-potency products and edibles, meaning food or drinks containing cannabis. An edible takes effect much later than smoked cannabis. People feel nothing at first, take more, and end up with far too much by accident.

For anyone with an anxiety-related condition, starting a high-THC product carries a real risk of making the condition worse. If an edible seems to do nothing, do not take a second dose. The forum’s guide to THC over-intoxication explains what helps and when to go to hospital.

Translator’s note: In Thailand, call the emergency medical number 1669 if a panic reaction does not settle. Call it too if the person seems confused or out of touch with reality.

Psychosis risk

Psychosis means losing touch with reality, for example hearing voices or holding false beliefs. Some people have had psychosis or a schizophrenia-spectrum disorder, or have a family member who has. In these people, cannabis use is linked to earlier and more severe psychotic symptoms. The risk is highest with high-potency THC products.

Marconi and colleagues (2016, Schizophrenia Bulletin) carried out a meta-analysis, which pools the numbers from many studies into one result. They found a dose-response relationship: more frequent use and more potent products went with a higher psychosis risk. Strength of evidence: meta-analysis of population studies.

This is why a doctor should check for psychosis risk before anyone with a mental health condition starts cannabis. Tell your doctor if you or any close relative has had psychosis or schizophrenia. This tells the doctor whether cannabis should be ruled out for you.

Does cannabis cause anxiety, or does anxiety lead to cannabis use?

Anxiety disorders are more common among cannabis users, especially among heavy, long-term users. There are three competing explanations:

  • Cannabis causes anxiety: Regular high-THC use changes the endocannabinoid system, the body’s own cannabis-like signalling network. This raises anxiety in the periods between uses. The person uses again for relief, and this cycle hides the fact that the anxiety is getting worse.
  • Anxiety leads to cannabis use: People with anxiety disorders use cannabis to treat themselves.
  • Shared vulnerability: Common factors make people prone to both conditions. These include genes and a stress response that does not work normally.

Mammen and colleagues (2018, Journal of Clinical Psychiatry) wrote a systematic review, which finds and selects studies by a fixed method. It covered prospective studies, which follow people forward over time. All participants were adults who already had an anxiety or mood disorder.

The review included 12 studies with 11,959 participants. In 11 of the 12 studies, recent cannabis use was linked to more severe symptoms over time. The review shows how existing disorders develop. It does not show that cannabis causes new anxiety diagnoses.

The authors name three limits. The studies only observed people. The groups studied were not fully representative, and the cannabis came from unregulated sources. Strength of evidence: a systematic review of observational studies.

In practice, anxiety disorders and cannabis use disorder often occur together, and the link probably runs both ways. Treating one without assessing the other leads to worse results. If your anxiety is getting worse in the hours or days between uses, tell your doctor and ask for both conditions to be assessed.

THC and CBD compared

Question THC, high dose THC, low dose CBD
Short-term anxiety Higher risk Slight calming effect Lower anxiety in public-speaking test studies
Psychosis-like effects Yes Rare None recorded
Risk of dependence Yes Lower Low to minimal
PTSD and nightmare data Smoked cannabis trial: no better than placebo (Bonn-Miller 2021) Nabilone, a man-made THC-like medicine: small crossover trial reduced nightmares (Jetly 2015) High-CBD group: no better than placebo (Bonn-Miller 2021)
Controlled-trial evidence for anxiety Limited; the main data are about risk Very limited Small trials; mixed (some positive, some found no effect)
Type of evidence Observational studies and studies of how it acts in the body Laboratory experiments Small trials and open-label studies (no comparison group)

For anxiety, products high in CBD and low in THC have the better balance of benefit and risk. Even for CBD, the evidence is not yet strong enough for treatment guidelines to recommend it. That applies both as a first treatment and as an add-on to other anxiety treatment.

If a doctor suggests a cannabis product for anxiety, ask for its THC and CBD content. Ask whether a CBD-dominant, low-THC product would suit you.

Cannabis alongside standard anxiety treatment

There are two separate concerns, and they should not be confused.

1. Talk therapy. Exposure-based CBT (cognitive behavioural therapy) works through fear extinction, as the brain learns that a feared situation is safe. In theory, using cannabis during treatment could change how new memories are stored. The benefits of therapy might then last less long. No clinical trial has tested this. A related hope was that CBD would strengthen exposure therapy, but Kwee and colleagues (2022) found it did not.

2. Medicines. CBD slows several liver enzymes, including CYP2C19. This enzyme helps break down several SSRIs, a common group of antidepressants also used for anxiety. CBD may therefore raise SSRI levels in the blood and make their side effects stronger. This concern has nothing to do with fear extinction. The forum’s drug-interaction list gives the details.

Doctors whose anxiety patients also use cannabis should ask about four things: how often, which product, what dose, and when it is used relative to anxious episodes and medicines. Doctors should also explain clearly what the evidence does and does not show.

Bring these four facts to your appointment yourself, written down. With them, the doctor can spot drug interactions. The doctor can also see whether your cannabis use comes before or after your anxious episodes.

The rules in Thailand

  • Flower is a controlled herb. The Notification of the Ministry of Public Health Re: Controlled Herbs (Cannabis) B.E. 2568 was issued under the Thai Traditional Medicine Protection Act B.E. 2542. It came into force on 26 June 2025.
  • Prescription only. Flower may be dispensed only with a PT 33 (ภ.ท.33) prescription from an authorised practitioner. Each prescription covers no more than 30 days.
  • No online sales, no advertising. Flower may not be advertised in any channel or sold online.
  • 2026 changes. Two Ministerial Regulations of B.E. 2569 tightened licensing. The Regulation on Cannabis or Hemp Extracts came into force on 26 April 2026. Under it, extracts with more than 0.2% THC are licensed only to three groups: Thai juristic persons that are not “foreign” under the Foreign Business Act B.E. 2542, state agencies and the Thai Red Cross Society. The Regulation on Controlled Herbs (No. 2) came into force on 30 April 2026 and tightens the licence criteria for cannabis flower.
  • The Cannabis Control Act is not law yet. The draft Act is still a draft. The Cabinet approved it on 22 September 2026 and sent it to the House of Representatives.
  • Clinical guidance. The Department of Medical Services (Ministry of Public Health) publishes Guidance on Cannabis for Medical Use (6th edition, 2024). It presents cannabis products as an option when standard treatment is unsuitable. It advises starting with a low dose and raising it slowly. If you have anxiety or PTSD, ask the prescriber how the current edition applies to your diagnosis.

In practice, if you are in Thailand and are considering cannabis for an anxiety disorder or PTSD, go through a licensed practitioner or a PT 33 clinic. Tell them about any mental health history and every medicine you take.

Translator’s note for growers: Friends or customers may ask you for flower “for anxiety”. Selling a controlled herb without a licence breaks Section 46 of the Thai Traditional Medicine Protection Act B.E. 2542. Under Section 78, the penalty is up to 1 year in prison, a fine of up to 20,000 baht, or both. Advertising flower is also prohibited. Do not post that a strain treats anxiety or PTSD. The forum’s advertising and selling rules explain what you may post. Refer anyone who asks to a PT 33 clinic.

Practical steps for patients under medical supervision

  1. Know that the dose can reverse the effect. Low THC doses may reduce anxiety, but high doses are likely to make it worse. The turning point differs between people and cannot be predicted in advance. Knowing this helps you recognise early when a dose is too high.

  2. Let the prescriber choose the product. For patients treated under medical supervision, high-CBD, low-THC products have better evidence and lower risk for anxiety than high-THC products. The treating practitioner should make the choice, based on your diagnosis and your medicines.

  3. Start low and raise slowly. Starting with the lowest available dose makes THC-triggered anxiety less likely. For CBD, nobody knows the dose that reduces anxiety for certain. It may also differ between a single dose and daily use (see the dosing guide).

  4. Avoid high-potency THC products. More potent products are linked to a higher risk of psychosis (Marconi 2016), and high THC doses drive anxiety. No proven THC percentage marks a safe limit. If you are prone to anxiety, choosing lower-THC products is the sensible default.

  5. Get checked for psychosis risk first. People with a personal history of psychosis, or a strong family history of it, should avoid cannabis, especially high-THC products. This check should happen before cannabis is started for any mental health condition.

  6. PTSD: keep the proven treatments. Cannabis is an unproven add-on for PTSD. It does not replace the first-line treatments with proven benefit. These are trauma-focused CBT, EMDR, and SSRI or SNRI medicines. EMDR (eye movement desensitisation and reprocessing) is a therapy in which you recall the trauma while following guided eye movements. SNRIs are another common group of antidepressants.

  7. Watch for dependence. In people with anxiety, using cannabis to treat themselves can lead to dependence. At each visit, the doctor should review four things: how often you use it, whether your dose keeps rising, whether it affects work or family life, and whether you get withdrawal symptoms when you stop.

Translator’s note: For mental health support in Thailand, you can call the Department of Mental Health hotline 1323. Use it if anxiety, panic or cannabis use is getting out of control.

Conclusion

The endocannabinoid system plays a role in fear, in unlearning fear and in the stress response. That is a sound reason to study cannabinoids in anxiety and PTSD. The PTSD brain scans, however, show a more complex picture. They found more CB1 receptors together with low anandamide, which points to changed signalling. They do not show a simple shortage that a THC-like medicine could correct.

The clinical trials have not confirmed the theory. For CBD in anxiety, the positive results are short-term and come mostly from social anxiety. The studies of hard-to-treat anxiety had no comparison group, and a trial adding CBD to exposure therapy was negative. In PTSD, the controlled evidence covers the man-made medicine nabilone for nightmares, in small groups. The key placebo-controlled trial of smoked cannabis found no advantage over placebo.

This evidence supports careful, individual, medically supervised use in selected patients. It does not support recommending cannabis broadly. For some patients, especially those who tolerate THC poorly, CBD-dominant treatment under medical supervision may give a small extra benefit. For others, cannabis will make symptoms worse. That harm depends on the dose, differs between people and can be prevented.

The research field still needs larger double-blind trials. They should study clearly defined patient groups, use standardised products and measure results with proven psychiatric scales.

If you live with anxiety or PTSD and are considering cannabis, book a consultation with a licensed practitioner. Bring your written list of products, doses and medicines. If you have questions about this article, post them below this topic.

References

  • Bergamaschi MM et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226.
  • Berger M et al. (2022). Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial. The Journal of Clinical Psychiatry, 83(5), 21m14130.
  • Bonn-Miller MO et al. (2021). The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PLoS One, 16(3), e0246990.
  • Jetly R et al. (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology, 51, 585–588.
  • Kwee CMB et al. (2022). Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial. European Neuropsychopharmacology, 59, 58–67.
  • Mammen G et al. (2018). Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies. The Journal of Clinical Psychiatry, 79(4), 17r11839.
  • Marconi A et al. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42(5), 1262–1269.
  • Masataka N. (2019). Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Frontiers in Psychology, 10, 2466.
  • Neumeister A et al. (2013). Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Molecular Psychiatry, 18(9), 1034–1040.
  • Stoner SA. (2017). Effects of marijuana on mental health: Anxiety disorders. Alcohol & Drug Abuse Institute, University of Washington. Retrieved from adai.uw.edu.
  • Department of Medical Services, Ministry of Public Health, Thailand. (2024). Guidance on Cannabis for Medical Use, 6th edition.